| (Values in U.S. Thousands) | Sep, 2017 | Jun, 2017 | Mar, 2017 | Dec, 2016 | Sep, 2016 |
| Sales | 4,010 | 4,240 | 3,790 | 3,540 | 3,250 |
| Sales Growth | -5.42% | +11.87% | +7.06% | +8.92% | +4.50% |
| Net Income | -610 | -370 | -520 | -560 | -860 |
| Net Income Growth | -64.86% | +28.85% | +7.14% | +34.88% | +30.65% |
Combimatrix Corp (CBMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
CombiMatrix Corporation is a diversified biotechnology business that develops proprietary technologies, including products and services in potential markets where their products and services can be utilized. The Company's products and services are specially utilized in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology and defense and homeland security markets. The technologies they have developed include a platform technology to rapidly produce user-defined, in-situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs.
Fiscal Year End Date: 12/31